Your Daily Brief
Swiss and European biotech news, every weekday.
-
Lonza, BioNTech, Evotec, Zealand Pharma, Oncopeptides
Lonza: higher profitability targets at its Capital Markets Day; BioNTech: BNT113 misses on progression-free survival, trial continues for overall survival; Evotec: nine-month figures above expectations, guidance confirmed; Zealand Pharma: AI protein deal with Generate Biomedicines; Oncopeptides: SEK 100M share issue for its glioblastoma programme.
-
PolyPeptide, Formycon
PolyPeptide: Samsung Biologics’ takeover offer clears its acceptance threshold; Formycon: FDA accepts the filing for Keytruda biosimilar FYB206.
-
Idorsia, Medincell, Ascelia Pharma
Idorsia: post hoc aprocitentan data at AHA Hypertension; Medincell: FDA approves Weltruza; Ascelia Pharma: Orviglance path after its FDA Type A meeting.
-
ADC Therapeutics raises $86.6M and resets its debt
Also: GenSight’s GS030 optogenetics trial in NEJM and a €1.0M raise; Pharvaris’ RAPIDe-3 HAE data in The Lancet.
-
Argenx halts efgartigimod Phase 3 in Sjögren’s
FDA keeps Newron hold, Zealand's petrelintide Phase 2 win, Bavarian Nordic lifts guidance, UK pulls Valneva's IXCHIQ.
-
Alvotech adds US capacity with LOTTE Biologics
Also: BridgeBio priority review, a rival to Ascendis; Lundbeck Parkinson's data; Forbion's €2.3bn funds; Alzinova rights issue.
-
Genmab’s epcoritamab succeeds in frontline DLBCL
Also: Alvotech's FDA capacity win, CSL–Alentis deal worth up to $1.6bn, new Idorsia data at AHA.